Trial Profile

Clinical trial and pharmacokinetic phase II 30-minute infusion of PM02734 [Irvalec] every three weeks in patients with metastatic non-small cell lung(NSCLC) previously treated squamous cell with at least one line of platinum-based chemotherapy. [Ensayo clinico y farmacocinetico de fase II de infusion de 30 minutos de PM02734 (Irvalec) cada tres semanas en pacientes con cancer no microcitico de pulmon (CNMP) epidermoide previamente tratado con al menos una linea de quimioterapia con platino]

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Apr 2012 Status changed from recruiting to discontinued.
02 Apr 2012 Planned End Date changed to 18 Nov 2010.
18 Dec 2008 Recruitment is expected to last 12 months, as reported by PharmaMar.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com